L
Luis M. Ruilope
Researcher at European University of Madrid
Publications - 891
Citations - 109166
Luis M. Ruilope is an academic researcher from European University of Madrid. The author has contributed to research in topics: Blood pressure & Renal function. The author has an hindex of 94, co-authored 841 publications receiving 97778 citations. Previous affiliations of Luis M. Ruilope include Lund University & Mayo Clinic.
Papers
More filters
Journal ArticleDOI
Serum uric acid and cardio-renal diseases
TL;DR: Clinical evidence suggests a relationship of UA level with incident chronic kidney disease (CKD), and the results of clinical trials using urate lowering therapy provide some promising evidence that lowering UA levels may retard the progression of CKD.
Journal ArticleDOI
Long-term protection in at-risk hypertensive patients--a role for nifedipine GITS?
TL;DR: The results from INSIGHT support incorporating nifedipine GITS in the management of high-risk hypertensive patients to prevent atherosclerosis-related illness and death.
Journal ArticleDOI
Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO‐DKD trial
Gerasimos Filippatos,Bertram Pitt,Rajiv Agarwal,Dimitrios Farmakis,Luis M. Ruilope,Peter Rossing,Johann Bauersachs,Robert J. Mentz,Peter Kolkhof,Charlie Scott,Amer Joseph,George L. Bakris,Stefan D. Anker +12 more
TL;DR: This prespecified analysis of the FIDELIO‐DKD trial compared the effects of finerenone, a selective non‐steroidal mineralocorticoid receptor antagonist, on cardiorenal outcomes in patients with chronic kidney disease and type 2 diabetes by history of heart failure.
Surrogate endpoints and renal protection: focus on microalbuminuria.
TL;DR: Studies from the laboratory suggest that reduction in albuminuria during ACE inhibition constitutes a predictor of an attenuated rate of decline in GFR in early diabetic nephropathy.
Journal ArticleDOI
Angiotensin receptor blockade in diabetic renal disease--focus on candesartan.
TL;DR: This short review contains the most relevant evidence in favour of angiotensin receptor blockers, with particular emphasis on the capacities of candesartan for controlling blood pressure and protecting the kidney.